Evidence-aware
Safety focused
Women’s Health Clinic FAQ
How effective is the O-Shot for bladder leakage?
The effectiveness of the O-Shot for bladder leakage depends on leakage type, severity, pelvic-floor function, childbirth history, menopause status, and other bladder symptoms. Some clinics market PRP for stress-type leakage.
Direct answer
The effectiveness of the O-Shot for bladder leakage depends on leakage type, severity, pelvic-floor function, childbirth history, menopause status, and other bladder symptoms. Some clinics market PRP for stress-type leakage.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Mechanism
Uses the patient's own blood spun in a centrifuge to extract platelet-rich plasma; growth factors stimulate collagen.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Suitability must be confirmed after consultation.
Important safety note
Safety: reported safety profile with low allergy or rejection risk. Minor Side Effects: Mild dysuria, spotting, localised pain, vaginal fullness. Rare Side Effects: Urinary retention, rare infection, hyper-arousal.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
not a definitive treatment and objectively inferior to mid-urethral slings for complete continence. Remains an investigational, off-label treatment not currently included in NICE or BSUG guidelines due to a lack of large-scale, long-term randomised controlled trials and high study heterogeneity.
Clinical context
not a definitive treatment and objectively inferior to mid-urethral slings for complete continence.
Evidence
Symptoms
Alternatives
What it means
not a definitive treatment and objectively inferior to mid-urethral slings for complete continence.
Why it happens
Symptoms may be linked to physical, hormonal, medication-related, psychological or relationship factors.
Evidence limits
Evidence may be developing, so the page should avoid promise-based language and explain uncertainty.
Treatment fit
Suitability depends on history, symptoms, examination where appropriate and discussion of alternatives.
What this means in practice
Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues. Cost: Usually out-of-pocket and not covered by standard health insurance.
Early Phase (Days 3–7): Initial changes in sensation. Tissue Development (Weeks 1–6): Regeneration accelerates; symptom improvement often noticed within 2-6 weeks. Peak Effect (Month 3): Final clinical outcomes reached. Durability: 12 to 18 months.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
not a definitive treatment and objectively inferior to mid-urethral slings for complete continence.
It protects safety
Safety: reported safety profile with low allergy or rejection risk. Minor Side Effects: Mild dysuria, spotting, localised pain, vaginal fullness. Rare Side Effects: Urinary retention, rare infection, hyper-arousal.
It reviews alternatives
Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues.
It sets expectations
Early Phase (Days 3–7): Initial changes in sensation. Tissue Development (Weeks 1–6): Regeneration accelerates; symptom improvement often noticed within 2-6 weeks.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues. Cost: Usually out-of-pocket and not covered by standard health insurance.
Consultation priorities
Pre-Assessment: Consultation, bladder diary, validated questionnaires, and cough stress test. Procedure Day: Blood draw, centrifugation, topical numbing, and rapid injection.
Consent
Aftercare
Follow-up
Before treatment
Pre-Assessment: Consultation, bladder diary, validated questionnaires, and cough stress test. Procedure Day: Blood draw, centrifugation, topical numbing, and rapid injection.
During care
The clinician should explain the procedure, likely sensations, limits and alternatives.
Aftercare
Written aftercare and follow-up should be clear before the patient leaves.
When to reassess
If expected improvement does not occur, the plan should be reviewed rather than repeated automatically.
Practical expectations
Early Phase (Days 3–7): Initial changes in sensation. Tissue Development (Weeks 1–6): Regeneration accelerates; symptom improvement often noticed within 2-6 weeks.
Costs, access and treatment plans should be confirmed before booking.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Effectiveness is the same for all bladder leakage.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: Patient stories are the same as predictable clinical outcomes.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: If PRP does not help, the patient has done something.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Marketing language should not outrun clinical evidence.
Alternatives
Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Safety: reported safety profile with low allergy or rejection risk. Minor Side Effects: Mild dysuria, spotting, localised pain, vaginal fullness. Rare Side Effects: Urinary retention, rare infection, hyper-arousal.
Are alternatives clear?
Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Safety: reported safety profile with low allergy or rejection risk. Minor Side Effects: Mild dysuria, spotting, localised pain, vaginal fullness. Rare Side Effects: Urinary retention, rare infection, hyper-arousal.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Safety: reported safety profile with low allergy or rejection risk. Minor Side Effects: Mild dysuria, spotting, localised pain, vaginal fullness. Rare Side Effects: Urinary retention, rare infection, hyper-arousal.
Bleeding or discharge
Unexplained bleeding, unusual discharge or new pelvic symptoms should be reviewed.
Infection signs
Fever, spreading redness, pus or feeling unwell after a procedure needs urgent advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The best page wins by being the clearest expectation-setting page in the market: useful for commercial search, but grounded in assessment and uncertainty.
Clinical reality
- not a definitive treatment and objectively inferior to mid-urethral slings for complete continence.
Timeline and expectations
- Early Phase (Days 3–7): Initial changes in sensation. Tissue Development (Weeks 1–6): Regeneration accelerates; symptom improvement often noticed within 2-6 weeks. Peak Effect (Month 3): Final clinical outcomes reached. Durability: 12 to 18 months.
Practical logistics
- Setting: Outpatient clinic. Preparation: 15-50 mL blood draw. anaesthesia: Topical local anaesthetic (e.g., 2% Lidocaine). Dosage: 5-6 mL injected into periurethral and anterior vaginal wall tissues.
Research sources
- Daneshpajooh et al. (2021) RCT comparing PRP to mid-urethral sling. 2. Chiang & Kuo (2022) Prospective study on mid-term durability. 3. Athanasiou et al. (2021) Prospective pilot study on symptom reduction. 4.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 156 imported records. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. Disclaimer: The information provided is for educational and informational purposes only and does not constitute medical advice. PRP therapy for stress urinary incontinence is currently considered an off-label and investigational treatment. Always consult a licensed urogynaecologist or qualified healthcare provider for a comprehensive evaluation and personalised medical guidance. Results vary. Not a cure.
